Antibody Discovery, Sequencing, and Characterization Services Powered by Mass Spectrometry.

Our patented technology and innovative services enable biotech and pharmaceutical companies to extract the full potential of antibodies. We tap directly into the immune response in ways never before possible.

Image

Decode Immunity with Antibody Sequencing.

We are empowering life science breakthroughs with next generation protein sequencing. Our technology and services enable biotech and pharmaceutical companies to extract the full potential of antibodies in ways never before possible.

Image

Antibody Discovery and Characterization Services Powered by Mass Spectrometry.

Our technology and services enable biotech and pharmaceutical companies to extract the full potential of antibodies and tap directly into immune response in ways never before possible.

  • Extract and sequence functional mAb proteins from serum with REpAb®
  • Sequence any monoclonal antibody or protein with our REmAb®
  • Epitope mapping with the highest resolution through HDX-MS
  • Full kinetic analysis and rapid screening of Antibody-Antigen binding with SPR

Antibody Sequencing & Discovery Services.

Antibody Sequencing & Discovery Services.

REmAb®

Monoclonal antibody sequencing from small protein samples, no need for hybridoma or DNA information. Full sequence in record time.
Antibody Sequencing Services

Image

REpAb®

Polyclonal antibody sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.
Antibody Discovery Services

Image

RapidHDX-MS™

Mass spectrometry-based epitope mapping. Epitope mapping to identify the binding site of an antibody to its corresponding antigen with the highest confidence and resolution.
HDX-MS Epitope Mapping Services

Image

RapidSPR™

Label-free evaluation of antibody-antigen binding through Surface Plasmon Resonance. Combined with our expertise in antibody interactions, this results in high sensitivity and the lowest noise even in complex analytes.
Explore SPR Services

Image

Decode Immunity.

We’re on a mission to empower life science breakthroughs with next generation protein sequencing.

Unlock Impossible Antibody Breakthroughs with Polyclonal Antibody Sequencing.

Groundbreaking software, technology and methods developed through our seamless integration of bioinformatics, mass spectrometry and pioneering research. Antibody sequencing and discovery platforms capable of delivering results where nobody else can.

Image
Image

Unlock Impossible Antibody Breakthroughs.

Groundbreaking software, technology and methods developed through our seamless integration of bioinformatics, mass spectrometry and pioneering research. Antibody sequencing and discovery platforms capable of delivering results where nobody else can.

Image
Image
Image

Unlock Impossible Antibody Breakthroughs.

Groundbreaking software, technology and methods developed through our seamless integration of bioinformatics, mass spectrometry and pioneering research. Antibody sequencing and discovery platforms capable of delivering results where nobody else can.

Image
Image
Image

Obtain the Full Antibody Sequence for your mAb.

Use protein sequencing in a high-throughput workflow to get faster answers, focus efforts and identify additional high-quality molecules that cannot be found through other methods. Avoid troubleshooting delays with easy and detailed structural insights, routinely.

Image
Image

Reduce Risk.

Increase probability of technical success. Understanding proteins better and sooner in your discovery process avoids downstream challenges. Testing both protein behavior and structure in every step of your workflow improves reproducibility issues. Protect your IP with sequence information.

Image
Image
Image

Reduce Risk.

Increase probability of technical success. Understanding proteins better and sooner in your discovery process avoids downstream challenges. Testing both protein behavior and structure in every step of your workflow improves reproducibility issues. Protect your IP with sequence information.

Image
Image
Image

Characterize Epitopes at High Resolution with Industry Leading Coverage.

Increase probability of technical success. Understanding proteins better and sooner in your discovery process avoids downstream challenges. Testing both protein behavior and structure in every step of your workflow improves reproducibility issues. Protect your IP with sequence information.

Image
Image
Image

Explore clinical applications for protein sequencing.

We have developed our unique ability to sequence proteins within complex mixtures into a clinical test for multiple myeloma. Sequencing a patient’s unique m-protein allows us to identify clonotypic signal peptides and track their quantity over time – leading to insights about response to treatment, prognostication, and potential relapse detection. Our test, called EasyM, is CLIA accredited.

Image
Image

Speed Up Antibody Discovery.

Use protein sequencing in a high-throughput workflow to get faster answers, focus efforts and identify additional high-quality molecules that cannot be found through other methods. Avoid troubleshooting delays with easy and detailed structural insights, routinely.

Image
Image
Image

Speed Up Antibody Discovery.

Use protein sequencing in a high-throughput workflow to get faster answers, focus efforts and identify additional high-quality molecules that cannot be found through other methods. Avoid troubleshooting delays with easy and detailed structural insights, routinely.

Image
Image
Image
Image

“Rapid Novor was tasked with finding highly specific, high affinity antibodies against an important target- and they delivered powerful antibodies fit-for-purpose. Such antibodies are not easily obtained yet the Rapid Novor approach proved immediately successful, despite our time-constrained and stringent demands.”

Matt Pope, VP of Client Services, SISCAPA
Image

“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”

Pavel Khrimian – Co-founder and CBO, Deka Biosciences
Image

“The sequences have allowed us to have an “insurance policy” of sorts for critical proteins used in our various products.”

David Ankrapp, Senior Research Scientist, NEOGEN

Talk to Our Scientists.

Why Choose Us for Your Next Breakthrough.

10,000+ successful sequencing projects
25+ Years of proteomics innovation
800+ Clients served

Upcoming Conferences.